The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

UBS analysts maintained a Buy rating for Alvotech SA (NASDAQ:ALVO) with a steady price target of $18.00, representing a 41% ...

In terms of how Stelara’s loss of exclusivity is likely to play out, “we’ve talked about the Humira erosion curve being probably the best thing to model,” Jennifer Taubert, J&J’s ...

The main focus in Teva’s innovative portfolio continues to be neuroscience and immunology, with clinical trials for three key ...

Investors are also waiting to see how generic competition shakes out for Stelara. Using AbbVie's (ABBV) Humira as a guide, the company and analysts alike see potential for a muted impact.

Investors are also waiting to see how generic competition shakes out for Stelara. Using AbbVie's (ABBV) Humira as a guide, the company and analysts alike see potential for a muted impact. Humira ...

Humira is forecast to fall to sixth place by ... "Johnson & Johnson and Mitsubishi Tanabe Pharma’s Stelara (ustekinumab) and Eli Lilly and Sumitomo Dainippon Pharma’s Trulicity (dulaglutide ...

During the study time period, Humira, Stelara and Skyrizi — which all can treat Crohn’s disease — are projected to have the largest price increases. The healthcare industry will also see cost ...

STELARA biosimilar competition to accelerate; HUMIRA erosion curve remains the best proxy. Negative impact of Part D re-design, as a percent to sales, will be consistently applied throughout the year.

Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...